pirtobrutinib
Selected indexed studies
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. (Lancet, 2021) [PMID:33676628]
- Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). (J Clin Oncol, 2025) [PMID:40479620]
- Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. (J Clin Oncol, 2023) [PMID:37192437]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). (2025) pubmed
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. (2021) pubmed
- Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. (2023) pubmed
- Pirtobrutinib. (2012) pubmed
- Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. (2023) pubmed
- Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. (2023) pubmed
- Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma. (2024) pubmed
- Pirtobrutinib: First Approval. (2023) pubmed
- Pirtobrutinib. (2006) pubmed
- Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma. (2025) pubmed